

May 22, 2020



## Corbus Pharmaceuticals Announces Publication of Two Abstracts at EULAR 2020 E-Congress

- First abstract highlights pre-clinical data linking lenabasum's mechanism of action to inhibiting inflammasome activation
- Second abstract outlines baseline characteristics of RESOLVE-1 patients in EU

**Norwood, MA, May 22, 2020 (GLOBE NEWSWIRE)** -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today announced the publication of two abstracts at the European League Against Rheumatism (EULAR) 2020 E-Congress that will be taking place June 3-6, 2020.

Summarized below are the abstract titles that were selected for publication. The abstracts are published in the electronic "[Abstract Book](#)," which is an official supplement to the "Annals of Rheumatic Diseases ARD." The publications are also available in the [Scientific Publications](#) section of Corbus' [website](#).

### Programme Number AB0152:

- Title: Lenabasum, a CB2 agonist, inhibits inflammasome activation
- Authors: Subba Chintalacharuvu, Corbus Pharmaceuticals, Inc.; Ping Zang, Corbus Pharmaceuticals, Inc.; Barbara White, M.D., Corbus Pharmaceuticals, Inc.; Sergei Atamas, M.D., Ph.D., Corbus Pharmaceuticals, Inc.
- Citation: Ann Rheum Dis, volume 79, supplement 1, year 2020, page 1372

### Programme Number AB0568:

- Title: Baseline European Patient Demographics and Disease Characteristics in a Phase 3 Study of Safety and Efficacy of Lenabasum, a CB2 Agonist, in Diffuse Cutaneous Systemic Sclerosis
- Authors: Robert Spiera, M.D., Hospital for Special Surgery Main Hospital, New York; Nancy Dgetluck, Corbus Pharmaceuticals, Inc.; Bradley Bloom, M.D., Corbus Pharmaceuticals, Inc.; Barbara White, M.D., Corbus Pharmaceuticals, Inc.; Christopher Denton, M.D., Ph.D., FRCP, University College London
- Citation: Ann Rheum Dis, volume 79, supplement 1, year 2020, page 1576

### About Lenabasum

Lenabasum is a rationally designed, oral, small molecule that selectively binds as an agonist to the cannabinoid receptor type 2 (CB2), resolves inflammation and limits fibrosis. CB2 is preferentially expressed on activated immune cells and on fibroblasts, muscle cells, and endothelial cells. In both animal and human studies conducted to date, lenabasum has induced the production of pro-resolving lipid mediators that activate endogenous pathways which resolve inflammation and speed bacterial clearance without immunosuppression. Data from animal models and human clinical studies suggest that lenabasum can reduce expression of genes and proteins involved in inflammation and fibrosis. Lenabasum has demonstrated promising activity in animal models of skin and lung inflammation and fibrosis in systemic sclerosis (SSc). Lenabasum is also active in animal models of lung infection and inflammation in cystic fibrosis and joint inflammation and scarring in rheumatoid arthritis.

Lenabasum has demonstrated acceptable safety and tolerability profiles in clinical studies to date. Lenabasum treatment was associated with improvement in multiple physician-assessed and patient-reported efficacy outcomes in Phase 2 studies in patients with diffuse cutaneous SSc and patients with dermatomyositis with active skin involvement but not currently active muscle involvement. Lenabasum treatment also was associated with a lower rate of and longer time to pulmonary exacerbations in a Phase 2 cystic fibrosis study.

Lenabasum is not approved for the treatment of systemic sclerosis, dermatomyositis, cystic fibrosis or systemic lupus erythematosus.

## **About Corbus**

Corbus Pharmaceuticals Holdings, Inc. is a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat inflammatory and fibrotic diseases by leveraging its pipeline of rationally designed, endocannabinoid system-targeting drug candidates. The Company's lead product candidate, lenabasum, is a novel, oral, selective cannabinoid receptor type 2 (CB2) agonist rationally designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis and systemic lupus erythematosus.

Corbus is also developing a pipeline of drug candidates targeting the endocannabinoid system. The pipeline includes CRB-4001, a 2nd generation, selective cannabinoid receptor type 1 (CB1) inverse agonist designed to be peripherally restricted. Potential indications for CRB-4001 include nonalcoholic steatohepatitis (NASH), among others. Corbus expects data from its Phase 1 safety study in 2020.

Lenabasum is not approved for the treatment of systemic sclerosis, dermatomyositis, cystic fibrosis or systemic lupus erythematosus. CRB-4001 is not approved for the treatment of NASH/NAFLD. For more information on Corbus' clinical programs, please visit [here](#).

Please visit [www.CorbusPharma.com](http://www.CorbusPharma.com) and connect with the Company on [Twitter](#), [LinkedIn](#), and [Facebook](#).

## **Forward-Looking Statements**

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of

1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company's product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management's current beliefs and assumptions.

These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential," "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors, including the potential impact of the recent COVID-19 pandemic and the potential impact of sustained social distancing efforts, on our operations, clinical development plans and timelines, which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company's filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

**Corbus Pharmaceuticals Contacts:**

Ted Jenkins, Senior Director, Investor Relations and Corporate Communications  
Phone: +1 (617) 415-7745  
Email: [ir@corbuspharma.com](mailto:ir@corbuspharma.com)

Lindsey Smith, Director, Investor Relations and Corporate Communications  
Phone: +1 (617) 415-7749  
Email: [mediainfo@corbuspharma.com](mailto:mediainfo@corbuspharma.com)

Christina Tartaglia  
Stern Investor Relations  
Phone: +1 (212) 362-1200  
Email: [christina.tartaglia@sternir.com](mailto:christina.tartaglia@sternir.com)



Source: Corbus Pharmaceuticals Holdings, Inc.